Halozyme Therapeutics, Inc. (BIT:1HALO)

Italy flag Italy · Delayed Price · Currency is EUR
46.22
0.00 (0.00%)
At close: May 26, 2025, 5:30 PM CET
-23.04%
Market Cap 5.77B
Revenue (ttm) 1.00B
Net Income (ttm) 449.06M
Shares Out n/a
EPS (ttm) 3.48
PE Ratio 12.86
Forward PE 8.87
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 44
Open 46.22
Previous Close 46.22
Day's Range 46.22 - 46.22
52-Week Range 43.05 - 60.94
Beta n/a
RSI 15.05
Earnings Date May 6, 2025

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 350
Stock Exchange Borsa Italiana
Ticker Symbol 1HALO
Full Company Profile

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.

Financial numbers in USD Financial Statements

News

There is no news available yet.